Faron Pharmaceuticals Oy (FRA:4FR) Other Stockholders Equity: €201.66 Mil (As of Dec. 2025)


FRA:4FR Faron Pharmaceuticals Oy FRA:4FR
28 GF Score
Price €0.49
! 4 Warning Signs
View Full Analysis

What is Faron Pharmaceuticals Oy Other Stockholders Equity?

Faron Pharmaceuticals Oy FRA:4FR +3.07% 28 Other Stockholders Equity is €201.66 Mil as of Dec. 2025. GuruFocus rates FRA:4FR with a GF Score™ of 28/100. The stock has 4 warning signs investors should review.

Faron Pharmaceuticals Oy's Other Stockholders Equity for the quarter that ended in Dec. 2025 was €201.66 Mil.

Faron Pharmaceuticals Oy's quarterly Other Stockholders Equity increased from Dec. 2024 (€184.97 Mil) to Jun. 2025 (€197.20 Mil) and increased from Jun. 2025 (€197.20 Mil) to Dec. 2025 (€201.66 Mil).

Faron Pharmaceuticals Oy's annual Other Stockholders Equity increased from Dec. 2023 (€154.36 Mil) to Dec. 2024 (€184.97 Mil) and increased from Dec. 2024 (€184.97 Mil) to Dec. 2025 (€201.66 Mil).

Faron Pharmaceuticals Oy Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Faron Pharmaceuticals Oy's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Faron Pharmaceuticals Oy Other Stockholders Equity Chart

Faron Pharmaceuticals Oy Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 116.49 129.55 154.36 184.97 201.66

Faron Pharmaceuticals Oy Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 154.36 184.87 184.97 197.20 201.66
FRA:4FR
28GF Score
Faron Pharmaceuticals Oy FRA:4FR
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Faron Pharmaceuticals Oy Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of €201.66 Mil mean?
Faron Pharmaceuticals Oy (FRA:4FR) has a Other Stockholders Equity of €201.66 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Faron Pharmaceuticals Oy and its competitors.
Is Faron Pharmaceuticals Oy's Other Stockholders Equity too high?
Faron Pharmaceuticals Oy's current Other Stockholders Equity is €201.66 Mil. Overall, Faron Pharmaceuticals Oy has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Faron Pharmaceuticals Oy's Other Stockholders Equity compare to VRTX and REGN?
Faron Pharmaceuticals Oy's Other Stockholders Equity of €201.66 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Faron Pharmaceuticals Oy and its competitors. Faron Pharmaceuticals Oy's current Other Stockholders Equity is €201.66 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Faron Pharmaceuticals Oy stock overvalued right now?
Faron Pharmaceuticals Oy (FRA:4FR) has a current Other Stockholders Equity of €201.66 Mil. The current Other Stockholders Equity is €201.66 Mil. Faron Pharmaceuticals Oy's overall GF Score™ is 28/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Faron Pharmaceuticals Oy (FRA:4FR), the current Other Stockholders Equity is €201.66 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Faron Pharmaceuticals Oy Business Description

Other Exchanges FARN:UKFARON:Finland
Address Joukahaisenkatu 6 B, Turku, FIN, 20520
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company. The company has one operating and reportable segment. The Group has a pipeline based on the receptors involved in the regulation of immune response in oncology, organ damage, and bone marrow regeneration. Faron is a late clinical stage drug discovery and development Group. The company includes Bexmarilimab in its pipeline. Bexmarilimab is Faron's wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and improve clinical outcomes by targeting myeloid cell function in the microenvironment and igniting the immune system against cancer.
28GF Score

Get the complete analysis for FRA:4FR

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.49
Price